Anti-vascular endothelial growth factor (VEGF) therapy has failed to improve survival in patients with some types of cancer such as metastatic colon or kidney cancer, whereas obesity was recently shown to have an effect on anti-VEGF responses in breast cancer patients [46]. Here, VEGFA is linked to kidney cancer.